Dry syndrome is better treated with hydroxychloroquine sulfate, which can improve the function of salivary glands and relieve symptoms such as joint pain, rash, fatigue and low fever. Hydroxychloroquine sulfate belongs to one of the anti-malarial drugs, the drug through the inhibition of prostaglandin synthesis, interfering with the release of monocyte interleukin-1, inhibit polymorphonuclear cell chemotaxis and phagocytosis and other pathways can play a role in improving the function of salivary glands of patients with desiccation syndrome, alleviate the symptoms of joint pain, skin rashes, malaise, low-grade fever and other symptoms, which is a commonly used therapeutic drugs for the treatment of desiccation syndrome. Common adverse drug reactions after the use of hydroxychloroquine sulfate include irritability, mood changes, dizziness, and blurred vision. Treatment with this drug is contraindicated in patients who are allergic to hydroxychloroquine sulfate drug components, in the presence of retinal or visual field changes due to any of the 4-aminoquinoline components, and in children. Note that before starting long-term treatment with this product, all patients should undergo an ophthalmologic examination. Thereafter, examinations should be performed at least annually. Hydroxychloroquine sulfate should be used under the supervision of a physician, and patients are advised to go to the rheumatology and immunology department of a regular hospital for detailed consultation and use the drug as prescribed.